You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In a recent regulatory filing, Thermo disclosed that it acquired Core Informatics for $94 million and Finesse Solutions for $220 million.
The IP stems from the work of Anjana Rao, who identified 5-hydroxymethylcytosine (5hmC) as a cancer diagnostic biomarker.
PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.
Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.
The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
The GeneReader will feature a new sequencing chemistry that Qiagen believes circumnavigates an ongoing IP dispute with Illumina and provides enhanced performance.
The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.
The email, which claimed the Broad Institute did not deserve key CRISPR patents, is one of several attention-grabbing items in newly released documents.
Illumina follows Agilent, Life Technologies, Affymetrix, Siemens, and Luminex in settling lawsuits alleging infringement of US Patent No 7,064,197.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.